San Francisco-based Medivation (NASDAQ: [[ticker:MDVN]]) and its partner, New York-based Pfizer (NYSE: [[ticker:PFE]]) said today that an experimental drug for Huntington’s disease failed in a pivotal clinical trial. The companies are now discontinuing development of the drug, dimebon, for Huntington’s, although a Phase III clinical trial is continuing for patients with mild-to-moderate Alzheimer’s disease.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
